Regulatory changes are a constant in AI-driven health tech. If you’re a security or compliance lead in this space, you have to keep up with the FDA’s shifting rules. We’re going to look at the FDA’s software bill of materials (SBOM) requirement for cyber devices, breaking down what it means for manufacturers and how it sets security expectations, using Medcrypt’s analysis and Aidoc’s public FDA record as our guideposts.
The software bill of materials mandate is now the working center of the FDA’s Cybersecurity Guidance for anyone making a cyber device. Looking at Aidoc’s public FDA Cybersecurity Guidance and its FDA Warning Letter history shows you exactly how the agency’s documentation rules and its enforcement actions are connected. A post from Medcrypt lays out the requirement, and this article will detail what it demands. We’ll be clear about what’s not in the public record, like specific documentation from Aidoc, and call those out as gaps instead of trying to guess.
What the Recorded Medcrypt Post Says the Rule Requires
Medcrypt’s page on the topic states that the FDA’s software bill of materials requirement for cyber devices became enforceable in October 2023. This rule forces cyber device manufacturers to document a complete software bill of materials. It’s a regulatory obligation, not a friendly suggestion, and it’s meant to bring more transparency and better security to medical devices that run on software. The actual law for including an SBOM in premarket submissions for these devices, Section 524B of the FD&C Act, kicked in on March 29, 2023, which then gave the FDA the power to start refusing premarket submissions that didn’t have adequate cybersecurity info, including the SBOM, as of October 1, 2023.
For anyone running security or compliance in health tech, this changes how you have to think about developing, documenting, and maintaining cyber devices. It’s all about knowing every single software component, both commercial and open-source, that’s running inside your medical device. Having that deep of an understanding is the only way to effectively find and fix security vulnerabilities over the entire life of the device. If you don’t have a solid SBOM, trying to patch a newly found vulnerability turns into a complete mess, a reactive fire drill instead of a planned, orderly process.
Why a Software Bill of Materials is an FDA Cybersecurity Guidance Question
The FDA is pushing for SBOMs because modern medical devices are getting incredibly complex and are all connected to each other. A lot of cardiac AI products, for example, are classified as SaMD (Software as a Medical Device) 🔵 and don’t even have a hardware component. These software-only devices, and all other cyber devices, are exposed to security threats that could risk patient safety, mess with data, or just break the device. The SBOM is now a core piece of the wider FDA guidance on cybersecurity for medical devices.
An SBOM is just a complete inventory of every piece of software in your device, all the libraries, modules, and other dependencies. This list lets manufacturers and healthcare providers see at a glance if a device is running a component with a known security hole. Say a major vulnerability is found in a common open-source library. With an SBOM, a manufacturer can instantly check which of their devices are impacted and start working on a fix. This kind of proactive work is the definition of good GMLP (Good Machine Learning Practice) 🟡 and fits right in with having a strong QMS / ISO 13485 🟡 system.
The FDA sees the SBOM as a basic tool for managing software supply chain risk. A physical product has a bill of materials for its hardware parts. A cyber device now needs the same thing for its software. Building this into your process helps smooth out the regulatory path for new devices because it forces you to think about cybersecurity from the very beginning of development, not as something you bolt on at the end.
How Aidoc’s Recorded FDA Cybersecurity Guidance and FDA Warning Letter Records Frame Enforcement
There’s no public record connecting Aidoc to Medcrypt, but Aidoc’s own FDA history, which includes both Cybersecurity Guidance and an FDA Warning Letter, gives us a real-world picture of how security rules are applied and what enforcement looks like. The public file on Aidoc makes it clear that cybersecurity is a major area of regulatory focus.
The fact that an FDA Warning Letter exists in Aidoc’s public record shows how serious the agency is about non-compliance. While we don’t have the specifics of that letter here, its very existence means the FDA found problems in the company’s operations big enough to warrant a formal write-up. For a cyber device company, that could mean anything from weak security controls, poor documentation, or not fixing known vulnerabilities.
If you’re in a security or compliance role, Aidoc’s public record is a good lesson that the FDA’s cybersecurity guidance, including the SBOM rule, has real teeth. If you can’t produce and maintain a complete SBOM, or if you don’t act on risks that your own documentation uncovers, you could be facing the same kind of enforcement. This is about maintaining patient trust and ensuring your AI health products have a future. You can search the FDA Warning Letter database yourself.
What the Record Does Not Show
It’s also important to see what isn’t in the public record. We know from Medcrypt’s post about the SBOM rule and its enforcement date, and we can see that Aidoc has a history with FDA Cybersecurity Guidance and a Warning Letter. What we can’t see are the specifics of Aidoc’s own SBOM documentation. There are no public numbers on what it costs to put an SBOM process in place, how many people it takes, or what Aidoc’s actual SBOM documents contain.
Also, you won’t find any vendor performance stats or guarantees in this brief. The lack of these specifics means that while we know what the FDA expects, the real-world difficulties of getting it done, and how a company like Aidoc actually responded, aren’t fully clear from the public info. This is the gap where security and compliance leads have to do their own homework, because while the rule applies to everyone, how you achieve compliance and the resources you put behind it will look different everywhere.
So, understanding the FDA’s software bill of materials requirement is non-negotiable for anyone making cyber devices. Medcrypt’s analysis and Aidoc’s public FDA history show that this rule is a very real part of compliance, sending a direct message about transparency and proactive security management. For health technology security and compliance leads, it’s simple: having strong SBOM practices is a regulatory imperative.
Frequently Asked Questions
When did the FDA’s software bill of materials (SBOM) requirement for cyber devices become enforceable?
The FDA’s SBOM requirement for cyber devices has been enforceable since October 2023. The statutory requirement for an SBOM in premarket submissions became effective on March 29, 2023, under Section 524B of the FD&C Act.
What is the primary purpose of the FDA’s SBOM requirement for medical devices?
The primary purpose is to enhance the transparency and security posture of medical devices incorporating software components. It helps manufacturers, healthcare providers, and regulatory bodies quickly identify if a device contains a component with a known vulnerability, facilitating proactive vulnerability management.
What are the potential consequences for device manufacturers who do not comply with the FDA’s SBOM requirements?
The FDA gained the authority to refuse to accept premarket submissions for cyber devices lacking adequate cybersecurity information, including the SBOM, starting October 1, 2023. Failure to comply could also lead to enforcement actions, as demonstrated by the existence of FDA Warning Letters for deficiencies in practices.
What information should be included in an SBOM for a cyber device?
An SBOM should provide a comprehensive list of all software components, including libraries, modules, and dependencies, used in a device. This includes both commercial and open-source software components.
